What is CIDP?
Chronic Inflammatory Demyelinating Polyneuropathy, or CIDP, is a neurological disorder that causes weakness, tingling, or numbness in the arms and legs. The symptoms of CIDP are caused by damage to the myelin sheath, which is a protective covering wrapped around the nerves of the arms and legs (peripheral nerves).1
We don't know the exact reason for its clinical symptoms, but CIDP is thought to be an autoimmune disorder, in which a patient's immune system mistakenly attacks the myelin sheath. This results in defects in the ability of nerves to conduct electrical impulses, resulting in the weakness, tingling and numbness characteristic of CIDP.1
Diagnosing CIDP can be challenging, because patients can have a wide range of clinical symptoms, and responses to treatment can vary.1 Early diagnosis is important, because patients are more likely to respond to treatment when it is begun early in the course of the disease.2
Diagnosis is usually made by a combination of symptoms and the results of nerve conduction studies, which measure the ability of nerves to conduct electrical signals. These tests can provide evidence of myelin damage.1
What can be done?
GAMMAKED is an IGIV therapy proven effective in reducing the neuromuscular disability of patients with CIDP and in preventing relapse.3,4
This information is not intended to be a substitute for professional medical care. You should consult your healthcare professional for specific information on the diagnosis, treatment, and clinical care for patients with CIDP.
References: 1. Mathey EK, Park SB, Hughes RAC, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973-85. 2. Steinberg JS, Koski CL. Guillain-Barré syndrome, CIDP and variants. An overview for the layperson. 10th ed. http://30g7el1b4b1n28kgpr414nuu.wpengine.netdna-cdn.com/wp-content/uploads/2012/01/OverviewENG.pdf. Accessed December 2, 2016. 3. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate/chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44. 4. GAMMAKED [package insert]. Ft. Lee, NJ: Kedrion Biopharma; 2016.